Evaluation Of Coronary Heart Disease Risk Among Patients With Type 2 Diabetes In Hospital Pulau Pinang, Malaysia by Majeed, Saif Aldin R. Abdul
 
 
 
EVALUATION OF CORONARY HEART DISEASE RISK 
AMONG PATIENTS WITH TYPE 2 DIABETES IN HOSPITAL 
PULAU PINANG, MALAYSIA 
 
 
 
 
by 
 
 
 
 
 
 
SAIF ALDIN R. ABDUL MAJEED 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements for the degree of 
Master of Science 
 
 
 
 
 
 
 
July 2011 
 
 
ii 
 
ACKNOWLEDGEMENTS 
 
First and foremost, I would like to acknowledge ALLAH, the Almighty, for giving 
me the required knowledge and every necessary provision needed for the 
accomplishment of this work, Alhamdulillah. 
I would like to express my gratitude and thanks to my respected supervisor, 
Professor Syed Azhar Bin Syed Sulaiman, the Dean of school of Pharmaceutical 
Science, Unversiti Sains Malaysia. I would like to thank him for being constantly 
available to help and advise me, for providing ongoing support at all stages of my 
project. His guidance and advices during this research encourages me during hard 
times. I was very fortunate to have been able to work with him.  
This thesis would not have been accomplished without the emotional support of my 
family: I would like to sincerely thank my wonderful father and my lovely mother 
for their love, support and encouragement. Thank you both for giving me the strength 
to reach my goal. I am so grateful to my dear brothers Mohammed, Taif and Taha.  
Thanks my beautiful family for the unceasing love and support.  
I am so gratitude to my best friends Hani and his family, Ali, Nahith, for your love, 
being patience with my frequent complaining, help and care. I am so blessed and 
lucky to have you all in my life. Thank you all. I would like to express my gratitude 
thanks to my friends Harith and Omar and their families for their infinite support and 
help from the moment I got to Malaysia. Thanks for your generosity and your 
brotherly cooperation during the period of this work. I would like to sincerely 
acknowledge my colleagues Dr. Ahmad Awaisu and Jafaar Al-Kurmanji for their 
help and precious advices. I would also like to thank my friends and colleagues from 
the School of Pharmaceutical Sciences, Universiti Sains Malaysia.  
iii 
 
TABLE OF CONTENT 
ACKNOWLEDGEMENTS   ......................................................................................... ii
TABLE OF CONTENT   .............................................................................................. iii
LIST OF TABLES   ...................................................................................................... vi
LIST OF APPENDICES   ........................................................................................... viii
LIST OF CONFERENCE PRESENTATIONS   .......................................................... ix
LIST OF ABBREVIATIONS   ...................................................................................... x
ABSTRAK   .................................................................................................................. xi
ABSTRACT   .............................................................................................................. xiv
CHAPTER ONE: INTRODUCTION                                                                            
1.1 Diabetes mellitus   ........................................................................................... 1
1.2 Coronary heart disease   .................................................................................. 2
1.3 Type 2 diabetes and coronary heart disease   .................................................. 3
1.4 Epidemiology and prevalence   ....................................................................... 4
1.5 Pathophysiology   ............................................................................................ 6
1.6 Coronary heart disease risk factors  ................................................................ 8
1.6.1 Hyperglycaemia   ..................................................................................... 8
1.6.2 Hypertension   ........................................................................................ 10
1.6.3 Dyslipidaemia   ...................................................................................... 11
1.6.4 Gender   .................................................................................................. 12
1.6.5 Obesity   ................................................................................................. 13
1.6.6 Age   ....................................................................................................... 15
1.7 Prevention   .................................................................................................... 15
1.7.1 Role of diet and exercise   ...................................................................... 16
1.7.2 Hyperglycaemia management   .............................................................. 17
1.7.3 Hypertension management   ................................................................... 17
1.7.4 Dyslipidaemia management   ................................................................. 18
1.8 Prediction engines   ....................................................................................... 19
1.9 Rational of the study   .................................................................................... 21
1.10 The study objectives   ................................................................................ 22
CHAPTER TWO: LITERATURE REVIEW                                                              
2.1 Introduction   ................................................................................................. 23
2.2 Literature review   ......................................................................................... 23
 
iv 
 
CHAPTER THREE: METHODOLOGY                                                                  
3.1 Research design   ........................................................................................... 37
3.2 Study setting   ................................................................................................ 37
3.3 Study population   .......................................................................................... 37
3.4 Sample size calculation and sampling technique   ........................................ 38
3.5 Ethical consideration   ................................................................................... 39
3.6 Data collection   ............................................................................................. 39
3.7 Laboratory findings   ..................................................................................... 40
3.8 Total CHD risk   ............................................................................................ 41
3.9 Data management   ........................................................................................ 42
CHAPTER FOUR: RESULTS                                                                                     44
4.1 Results   ......................................................................................................... 44
4.2 Socio-demographic characteristics of the study population.   ....................... 45
4.3 Clinical factor characteristics of the study population.   ............................... 49
4.4 CHD risk factors characteristics of the study population.   ........................... 51
4.5 Assessment of coronary heart disease risk among the study population using 
UKPDS risk engine.   ............................................................................................... 56
4.6 Assessment of the target outcome for the CHD risk factors among the study 
population.   .............................................................................................................. 56
4.7 Association of socio-demographic factors with the predicted 10-year CHD 
risk…………..   ........................................................................................................ 58
4.8 Evaluation of clinical factors associated with the predicted 10-year CHD 
risk………….   ......................................................................................................... 61
4.9 Evaluation of CHD risk factors associated with the predicted 10-year CHD 
risk………..   ............................................................................................................ 65
4.10 Assessment of glycaemic control among the study population.   .............. 68
4.11 Evaluation of socio-demographic factors associated with the glycaemic 
control among study population.   ............................................................................ 68
4.12 Evaluation of clinical factors associated with the glycaemic control 
among study population.   ........................................................................................ 71
4.13 Evaluation of CHD risk factors associated with the glycaemic control 
among study population.   ........................................................................................ 74
4.14 Evaluation of glycaemia associated with the 10-year predicted CHD risk 
among study population.   ........................................................................................ 76
v 
 
CHAPTER FIVE: DISCUSSION                                                                                
5.1 Discussion   ................................................................................................... 77
5.1.1 Socio-demographic characteristics  ....................................................... 77
5.1.2 Clinical factor characteristics   ............................................................... 79
5.1.3 CHD risk factor characteristics   ............................................................ 81
5.1.4 Assessment of the overall 10-year predicted CHD   .............................. 82
5.1.5 Assessment of the target outcome for CHD risk factors   ...................... 84
5.1.6 Determination of the factors affecting the 10-year predicted CHD risk
  ………………………………………………………………………..85
5.1.7 Assessment of overall glycaemic control   ............................................. 91
5.1.8 Determination of factors affecting glycaemic control   ......................... 92
5.1.9 Association of glycaemia and CHD risk   .............................................. 94
5.2 Conclusion   ................................................................................................... 95
5.3 Future research and recommendations   ........................................................ 96
5.4 The study limitations   ................................................................................... 97
REFERENCES   ........................................................................................................... 98
APPENDICES   ......................................................................................................... 120
 
vi 
 
LIST OF TABLES 
 
Table 
number 
Title Page 
   
Table 4.1 Socio-demographic data distribution among study patients 45 
Table 4.2 Distribution of race within gender 46 
Table 4.3 Distribution of race within age groups 46 
Table 4.4 Distribution of gender within age groups 47 
Table 4.5 Distribution of gender within body mass index (Kg/m2 47 ) 
groups 
Table 4.6 Distribution of race within body mass index (Kg/m2 48 ) groups 
Table 4.7 Distribution of body mass index (Kg/m2 48 ) groups within age 
groups 
Table 4.8 Clinical data distribution among study patients 50 
Table 4.9 Mean value for CHD risk factors among study patients 51 
Table 4.10 Mean CHD risk factors values difference between gender 52 
Table 4.11 Mean CHD risk factors values difference between races 53 
Table 4.12 Mean CHD risk factors values difference between BMI 
groups 
54 
Table 4.13 Mean CHD risk factors values difference between age groups 55 
Table 4.14 Distribution of the three CHD risk groups 56 
Table 4.15 Distribution of the therapeutic outcome targets among the 
study population 
57 
Table 4.16 Comparing socio-demographic variables according to CHD 
risk 
59 
Table 4.17 Association between socio-demographic variables and CHD 
risk score 
60 
Table 4.18 Comparing clinical factor variables according to CHD risk 
score 
62 
Table 4.19 Association between clinical factor and CHD risk score 64 
Table 4.20 Comparing CHD risk factors control variables according to 
CHD risk score 
66 
Table 4.21 Association between CHD risk factor control variables and 
CHD risk score 
67 
Table 4.22 Distribution of the glycaemic control groups 68 
Table 4.23 Comparing socio-demographic variables according to their 
mean glycaemia 
69 
Table 4.24 Association between socio-demographic factors and 
glycaemic control 
70 
vii 
 
Table 
number 
Title Page 
   
Table 4.25 Comparing clinical characteristic variables according to their 
mean glycaemia 
72 
Table 4.26 Association between clinical factors and glycaemic control 73 
Table 4.27 Comparing CHD risk factors control variables according to 
their mean glycaemia 
74 
Table 4.28 Association between CHD risk factors and glycaemic control 75 
Table 4.29 Comparing glycaemic control group according to their mean 
10-year predicted CHD risk score 
76 
Table 4.30 Association between 10-year predicted CHD risk score groups 
and glycaemic control 
76 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
LIST OF APPENDICES 
 
Appendix A Request letter for permission to conduct the research at Hospital 
Pulau Pinang 
Appendix B Approval letter from NIH 
Appendix C Approval letter from Head of Internal Medicine Department 
Appendix D Approval letter from the Head of Diabetes Clinic Department 
Appendix E Data collection form 
Appendix F United Kingdom Prospective Diabetes Study (UKPDS) software 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF CONFERENCE PRESENTATIONS 
1- Saif Aldin R. Abdul Majeed, Syed A. Sulaiman, Hani Kareem Hamoodi. 10-
year risk prediction of the coronary heart disease in subjects with type 2 
diabetes mellitus using UKPDS engine in Penang. [poster presentation] 4th 
Asian Association of Schools of Pharmacy, 9th 
2- 
MPS-Pharmacy Scientific 
Conference 2009 (AASP-MPSPSC 2009). 
Saif Aldin R. Abdul Majeed, Syed A. Sulaiman, Hani Kareem Hamoodi. Risk 
of coronary heart disease in type 2 diabetes estimated using UK prospective 
diabetes study risk engine in Penang. [poster presentation] 
3- Abdul Majeed S.A.R, Sulaiman S.A.S, Hamoodi H.K. Cardiovascular event 
risk in type 2 diabetes mellitus patients in Penang General Hospital. [poster 
presentation] The 10
ACCP conference 
2009, September 26-28, Coex, Seoul, Korea. 
th
4- Abdul Majeed S.A.R, Sulaiman S.A.S., Hamoodi H.K. Glycaemic control in 
patients with type 2 diabetes in Penang. [poster presentation] The 10
 Asian Conference in Clinical Pharmacy ACCP, 9-12 
July, 2010 Singapore. 
th Asian 
Conference in Clinical Pharmacy ACCP, 9-12 July, 2010 Singapore. 
x 
 
LIST OF ABBREVIATIONS 
ACE inhibitor Angiotensin Converting Enzyme inhibitor 
ADA American Diabetes Association 
BHS British Hypertension Society 
BMI Body Mass Index 
CHD Coronary Heart Disease 
CVD Cardiovascular Disease 
DBP Diastolic Blood Pressure 
FBS Fasting Blood Sugar 
HbA1c Haemoglobin A1c 
HDL-cholesterol High Density Lipoprotein Cholesterol  
JBS Joint British Societies 
LDL-cholesterol Low Density Lipoprotein Cholesterol 
NICE National Institute for Health and Clinical Excellence 
NHMS III Third National Health and Morbidity Survey 
NSF National Service Framework 
SBP Systolic Blood Pressure 
TC Total Cholesterol 
UKPDS United Kingdom Prospective Diabetes Study 
VLDL-cholesterol Very Low Density Lipoprotein 
WHO World Health Organization 
 
 
 
xi 
 
PENILAIAN RISIKO PENYAKIT JANTUNG KORONARI 
DALAM KALANGAN PESAKIT DENGAN DIABETES JENIS 2 
DI HOSPITAL PULAU PINANG, MALAYSIA. 
ABSTRAK 
Prevalens diabetes mellitus meningkat dengan begitu ketara sekali dalam kalangan 
penduduk Malaysia sejak beberapa dekad yang lalu. Di samping itu, penyakit 
kardiovaskular (CVD) merupakan penyebab utama bagi morbiditi dan kematian / 
kematian di Malaysia. Pesakit diabetes mudah mendapat penyakit jantung koronari 
(CHD) daripada mereka yang tidak menghidap diabetes. Tambahan pula, pesakit 
diabetes yang tiada bukti klinikal CHD berisiko mengalami  CHD yang sama seperti 
pesakit tanpa diabetes tetapi menghidap CHD.  Faktor risiko klasik CHD memainkan 
peranan penting dalam usaha menganggar atau menentukan risiko CHD dalam 
kalangan pesakit diabetes. Faktor tersebut adalah umur, jantina, tabiat merokok,  
hiperglisemia, hipertensi, dislipidemia  dan obesiti.  
Kaedah epidemiologi dan biostatistik dibangunkan untuk meramal CHD.  Enjin 
risiko UKPDS (United Kingdom Prospective Diabetes Study) menggabungkan 
persamaan matematik ke dalam suatu model untuk mengira risiko mutlak insidens 
CVD. Kalkulator risiko UKPDS digunakan khusus bagi pesakit diabetes jenis 2.  
Selanjutnya, ia memasukkan  HbA1c (glycated haemoglobin) sebagai satu 
pembolehubah berterusan dan masa,  semasa diagnosis diabetes.    
Penyelidikan ini bermatlamat menilai risiko 10-tahun CHD dalam kalangan pesakit 
diabetes jenis 2, dengan menggunakan kalkulator enjin risiko UKPDS khusus dan 
faktor yang berkaitan.  Di samping itu, dikaji juga natijah sasaran faktor risiko CHD 
berdasarkan Garis Panduan Diabetes Malaysia.  Akhir sekali, kajian ini turut 
xii 
 
mengkaji perkaitan di antara kawalan glisemia dengan faktor risiko CHD.  Untuk 
mencapai matlamat ini, suatu kajian  rentas silang retrospektif dijalankan di Klinik 
Pesakit Luar Diabetes, Hospital Pulau Pinang. Pesakit  kajian didiagnosis dengan 
diabetes jenis 2, berumur dalam lingkungan  25-65 tahun; tempoh menghidap 
diabetes  di antara 1-20 tahun. Kajian ini tidak melibatkan pesakit dengan sejarah 
CHD atau sejarah CHD keluarga dan pesakit dengan diabetes gestasi (gestational 
diabetes). Kajian ini merekrut seramai 1000 orang pesakit (529 lelaki dan 471 
perempuan). Ramalan risiko 10-tahun CHD dikira menggunakan enjin risiko 
UKPDS. 
Kebanyakan daripada populasi kajian (43.9% Cina, 32% Melayu dan 24.1% India) 
berumur dalam lingkungan 50-59 tahun. Ramai pesakit menghidap hipertensi dan 
dislipidemia. Faktor risiko CHD tidak dikawal dengan baik oleh kebanyakan pesakit. 
Total 10-tahun CHD dianggar adalah  17.81% ±10.9 dan kebanyakan pesakit 
tergolong dalam kumpulan berisiko tinggi dan sangat tinggi.  Pesakit lelaki, berumur 
dalam lingkungan  50-56 tahun, mempunyai berat badan berlebihan atau yang 
terlampau gemuk mempunyai risiko yang lebih tinggi mendapat CHD daripada yang 
lain.  Perokok tegar (active smokers) mempunyai risiko yang lebih tinggi daripada 
mereka yang bukan perokok  (24.30 vs 16.41, p < 0.001). Selanjutnya, pesakit 
dengan tempoh menghidap diabetes yang lebih panjang mempunyai risiko yang lebih 
tinggi daripada pesakit yang baru didiagnosis.   Jenis terapi hipoglisemia oral yang 
digunakan  mempunyai kesan yang signifikan terhadap perkembangan risiko CHD. 
Penentu risiko CHD  dalam kalangan populasi diabetes di Malaysia adalah  HbA1c, 
gula-darah puasa (fasting blood sugar), trigliserida, HDL-kolesterol, LDLkolesterol, 
dan total kolesterol. Keputusan kajian menunjukkan bahawa min HbA1c bagi total 
populasi adalah  8.36% ± 2.3. Lelaki mempunyai tahap glisemia yang lebih baik 
xiii 
 
daripada perempuan  (8.22 vs 8.53, p < 0.001). Cina mempunyai tahap glisemia yang 
lebih baik daripada bangsa lain (7.92 vs 8.69 bagi Melayu dan 8.74 bagi India). 
Pesakit yang mempunyai berat badan yang berlebihan dan yang terlampau gemuk 
secara signifikannya mempunyai tahap glisemia yang lebih tinggi daripada pesakit 
lain. Pesakit dengan gabungan terapi menunjukkan tahap glisemia yang lebih tinggi 
daripada pesakit yang lain.  Pesakit dengan kawalan glisemia yang tidak begitu baik 
secara signifikannya mempunyai risiko yang lebih tinggi mendapat CHD dalam 
kalangan populasi kajian.   
Kajian merumuskan bahawa perkembangan  CHD dalam kalangan populasi diabetes 
jenis 2 di Malaysia adalah tinggi.  Kebanyakan pesakit tidak dirawat dengan aspirin 
dan / atau statin.  Faktor penentu yang memberi kesan pada risiko perkembangan 
CHD adalah  gender, penuaan, indeks jisim badan (body mass index, BMI), 
dislipidemia, tempoh menghidap diabetes  dan jenis agen  hipoglisemia  oral yang 
digunakan. 
Kajian ini  juga menunjukkan bahawa faktor risiko  CHD tidak dikawal dengan baik 
dalam kalangan kebanyakan pesakit diabetes jenis 2 di Malaysia.  Di samping itu, 
glisemia tidak dikawal dengan baik dalam kalangan populasi diabetes di Malaysia 
dan terlalu sedikit pesakit yang berusaha mengawalnya dengan baik. Di samping itu, 
kajian melaporkan bahawa    glisemia dikaitkan dengan risiko perkembangan CHD. 
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EVALUATION OF CORONARY HEART DISEASE RISK 
AMONG PATIENTS WITH TYPE 2 DIABETES IN HOSPITAL 
PULAU PINANG, MALAYSIA 
ABSTRACT 
The prevalence of diabetes mellitus had increased tremendously in the Malaysian 
population during the last decade. In addition to that, cardiovascular disease (CVD) 
reported to be an important cause of morbidity and mortality in Malaysia. Patients 
with diabetes are more likely to develop coronary heart disease (CHD) than a non 
diabetic population. Moreover, patients with diabetes but without clinical evidence of 
CHD own the same risk for CHD events as patients without diabetes but with CHD. 
The classical risk factors for CHD play an important role in the CHD risk estimation 
among patients with diabetes. These risk factors are age, gender, smoking status, 
hyperglycaemia, hypertension, dyslipidaemia and obesity.  
The prediction of CHD goes back to the development of epidemiological and 
biostatistical methods. The United Kingdom Prospective Diabetes Study (UKPDS) 
risk engine incorporates mathematical equations into a model which calculates the 
absolute risk of incident cardiovascular disease (CVD). The UKPDS risk calculator 
is used specifically for patients with type 2 diabetes. Furthermore, it includes 
glycated haemoglobin (HbA1c) as a continuous variable and the time since diagnosis 
of diabetes. 
This research aimed to estimate the predicted 10-year CHD risk among patients with 
type 2 diabetes using the diabetes specific UKPDS risk engine calculator and the 
factors associated with it. It also examined the target outcome for the CHD risk 
factors according to the Malaysian Diabetes Guideline. Finally, it investigated the 
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association of glycaemic control with CHD risk. To achieve this, a retrospective 
cross sectional study was conducted at the Outpatient Diabetes Clinic in Hospital 
Pulau Pinang. The patients included in the study were diagnosed with type 2 
diabetes, between 25-65 years; their diabetes duration was between 1-20 years. The 
study excluded patients with the history or with family medical history of CHD and 
patients with gestational diabetes. One thousand patients (529 male) were recruited 
in the study. The 10-year predicted CHD risk was calculated using the UKPDS risk 
engine.  
The age of the study population (43.9% Chinese, 32% Malay and 24.1% Indian) was 
mostly between 50-59 years. Most of the patients were hypertensive and 
dyslipidaemic. The CHD risk factors were poorly controlled among a majority of the 
patients. The total 10-year estimated CHD was 17.81% ±10.9 and most of the 
patients were within the high (44.7%) and very high risk (12%) groups. Patients who 
were male, between 50-56 years in age, overweight or obese had a higher risk of 
developing CHD than others. Active smokers had higher risk than non smokers 
(24.30% vs 16.41%, p < 0.001). Moreover, patients with longer diabetes duration had 
a higher risk than newly diagnosed patients. The type of oral hypoglycaemic therapy 
used had significant effect on CHD risk development. The determinants of CHD risk 
among Malaysian diabetes population were HbA1c, fasting blood sugar, triglyceride, 
high density lipoprotein (HDL-cholesterol), low density lipoprotein (LDL-
cholesterol) and total cholesterol. The study results showed the mean HbA1c of the 
total population was 8.36% ± 2.3. Males had better glycaemia levels females (8.22 vs 
8.53, p < 0.001). Chinese had better glycaemia than other races (7.92 vs 8.69 for 
Malay and 8.74 for Indians, p < 0.001). Overweight and obese patients had 
significantly higher glycaemia than others. Patients with combination therapy 
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showed a higher glycaemia than others. Patients with poor glycaemic control had 
significantly higher risk of developing CHD among the study population. 
The study concluded that the risk of developing CHD among type 2 diabetes 
Malaysian population was high. The study also showed that the CHD risk factors 
were poorly controlled among most of the Malaysian patients with type 2 diabetes. 
Furthermore, glycaemia was very poorly controlled among the Malaysian diabetic 
population and very few patients showed an adequate control. 
 In addition, the study reported that glycaemia was associated with the risk of 
developing CHD. The determinant factors that had an effect on the risk of 
developing CHD were gender, aging, body mass index (BMI), dyslipidaemia, 
smoking status, diabetes duration and the type of oral hypoglycaemic agents used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 CHAPTER ONE: INTRODUCTION 
 
1.1 Diabetes mellitus 
Diabetes is a disease characterized by the relative or absolute lack of insulin. This 
chronic disease is known by its symptomatic increase in lipid, protein metabolism 
and blood glucose concentration (Koda-Kimble et al., 2005). Hyperglycaemia and 
the other metabolic abnormalities associated with diabetes contribute to the 
development of complications such as cardiovascular complications, retinopathy, 
nephropathy and neuropathy (Fowler, 2008). Lately, it is well recognized that 
diabetes mellitus can be classified in to different types with different etiologies, in 
spite of the similarity that could occur in their pathologic sequences, after the onset 
of disease (Koda-Kimble et al., 2005).  
Type 1 diabetes is also known as insulin-dependent diabetes. It results from 
autoimmune pancreatic beta-cells destruction which causes an absolute insulin 
deficiency. It most commonly afflicts individuals around the time of puberty (Koda-
Kimble et al., 2005). Type 1 diabetes is treated by insulin, diet and exercise 
(Poretsky, 2002).  
Type 2 diabetes is also known as non-insulin-dependent diabetes mellitus. It results 
when insulin secretion is insufficient for maintaining glucose homeostasis, although 
pancreas preserves some beta-cell function. Type 2 diabetes is also known as adult-
onset diabetes (Howlett et al., 2003). Moreover, the development of type 2 diabetes 
is affected by genetic factors, environmental factors, obesity, physical activity, birth 
weight and diabetic pregnancy (Alberti and Zimmet, 1998).  
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Type 2 diabetes is treated by diet, exercise and oral anti-diabetic agents; insulin is 
used when the oral anti-diabetic agents fail to sustain glycaemic control. Oral anti-
diabetic drugs that are used in type 2 diabetes include: sulfonylurea, biguanides, α-
glucosidase inhibitors, thiazolidinediones and non-sulfonylurea insulin secretogogues 
(Koda-Kimble et al., 2005). 
Type 2 diabetes considered as a main public health problem in both developed and 
developing countries. In developing countries, the growing prevalence of type 2 
diabetes presents both a health and an economic challenge (Apparico et al., 2007). 
1.2 Coronary heart disease  
Coronary heart disease (CHD) is a condition characterized by the accumulation of 
plaque inside the coronary arteries. Coronary arteries responsible for cardiac muscle 
supply with oxygen-rich blood. Plaque consists of fat, cholesterol, calcium, and other 
substances found in the blood. The accumulation of plaque in the arteries is called 
atherosclerosis. The blood flow to the cardiac muscle is reduced due to the partial or 
complete block by the plaque. The low oxygen-rich blood supply to the cardiac 
muscle causes angina pectoris. Angina is characterized by chest pain or discomfort. 
If the chest pain persists without medical interruption for prolonged periods this 
causes irreversible myocyte damage which is known as myocardial infarction 
(Kasper et al., 2005; McPhee et al., 1997).  
Cardiovascular diseases’ (CVD) prevalence is increasing rapidly in developing 
countries because of the increase in the adoption of western diet and lifestyle (Ghali, 
1991, Manton, 1988). In Malaysia, CVD is an important cause of morbidity and 
mortality. CVD is considered for about a fifth of the total burden of disease in 
Malaysia by the year 2000. CHD is considered for 50 % of the cardiovascular burden 
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(Ministry of Health Malaysia, 2004b). In 2006, CVD was the commonest cause of 
deaths in government hospitals accounting for 24.2 % of total deaths (Ministry of 
Health Malaysia, 2008c). Management of CHD includes modification of risk factors, 
lifestyle changes, medical therapy and revascularization procedures (Ministry of 
Health Malaysia, 2009a). High diabetes and hypertension prevalence have a major 
contribution to the worsening of cardiovascular health in the developing countries 
(Zaini, 2000). 
1.3 Type 2 diabetes and coronary heart disease 
Type 2 diabetes is considered as a significant risk factor for CHD (Haffner et al., 
1998). This problem is amplified by the total number of individuals with diabetes; 
approximately 246 million people worldwide (Adler, 2008a). Although that there is 
no record of absolute time specific risk levels of CHD among diabetic population, it 
is well known that diabetic population are capable of developing CHD 2-4 times 
more likely than patients without diabetes (Haffner et al., 1998). Furthermore, it is 
recommended to consider patients with diabetes and no clinical evidence of CVD 
have the same risk for CHD events as patients without diabetes but with established 
CHD (Expert Panel on Detection Evaluation, 2001).  
Presently, about 20 % of patients with diagnosed CHD have an underlying disease of 
diabetes (Malmberg et al., 2000; Lowel et al., 2000; McGuire et al., 2000; Mukamal 
et al., 2001; Laskey et al., 2002), and the prevalence of undiagnosed diabetes is also 
high among patients with CHD (Norhammar et al., 2002). Coronary heart and 
cerebrovascular disease are a serious cause of morbidity and mortality (Kannel et al., 
1976; Fuller et al., 1983). Most importantly, the mortality of patients with diabetes 
having an acute coronary event is 50 % greater than in patients without diabetes 
(Malmberg and Ryden, 1988; Malmberg et al., 2000).  
 4 
The classical risk factors for CHD which is age, smoking status, hypertension, and 
dyslipidaemia play an important role in the prediction of CHD risk in patients with 
diabetes (Turner et al., 1998b; Davis et al., 1999). Clinical trials showed that risk 
factor interventions cause reduction in CHD risk in diabetic and non-diabetic 
individuals. But the absolute advantage for the diabetic population is even greater 
due to higher absolute CHD risk (Adler, 2008b). Such evidence is available on 
blood-pressure-lowering drugs (Curb et al., 1996; Hansson et al., 1998; Tuomilehto 
et al., 1999), lipid-lowering drugs (Pedersen et al., 2000; Rubins et al., 1999; 
Lindholm, 2003), anti platelet drugs (Antithrombotic Trialists' Collaboration, 2002), 
beta-blockers (Gundersen and Kjekshus, 1983) and ACE-inhibitors (Moye et al., 
1994; Torp-Pedersen et al., 1996; Zuanetti et al., 1997). Joint British Societies (JBS) 
have recommended that primary prevention of CHD should be based on the 
assessment of absolute CHD risk (Jackson, 2000). 
1.4 Epidemiology and prevalence   
Population studies have clearly showed that the enormous rose in type 2 diabetes 
prevalence all over the world make it very likely that the situation is heading towards 
epidemic levels. From 1985 to 1995, the estimated diabetes population in the world 
rose from 30 million to 135 million. Based on this, epidemiologists predict that the 
diabetic population will bulge to 300 million by the year 2025, with nearly half of 
them will be in the Asia and Oceania region alone. It has been pointed out that there 
will be an expected rise of about 42% in developed countries while developing 
countries will escalate to 170% (King et al., 1998).There will be a huge rise of the 
disease in Asia and many of these will be seen in China (40 million) and India (55 
million) according to the vast numbers of people in these countries. However, the 
other rapidly developing countries in Asia such as Malaysia, Singapore, and Thailand 
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will experience the surge (Zaini, 2000). Diabetes and its complications is a major 
threat and expected to cause escalation to the public health resources, economic and 
social costs (Chuang et al., 2002).  
Malaysia is one of the countries that will be highly affected due to the major shift in 
the patterns of life and longevity of the population. It is clear that Malaysia has the 
right elements to set the scene for the outburst of diabetes like the rest of 
Asia. Malaysia, which has a multiethnic population, is expected to reach around 33.7 
million by the year 2020.  The three principal races of Malaysia are Chinese, Indians 
and Malays. So, if China and India countries are on the verge to exceed the 
international prevalence rate of type 2 diabetes, their respective counterparts in 
Malaysia will be much worse. The diabetes prevalence in Malaysia has steadily risen 
from 0.6% in 1960, to 2.1% in the 1982, and 6.3% in 1986 (Zaini, 2000). The Third 
National Health and Morbidity Survey (NHMS III) showed that the prevalence of the 
type 2 diabetes rose to 14.9% , which is almost 79.5% in the space of 10 years from 
1996 to 2006 (Ministry of Health Malaysia, 2009b). The Indians had the highest 
prevalence of 19.9% followed by Malays 11.9% and Chinese 11.4% (Letchuman et 
al., 2010). The demographic pattern has also changed to a large extent. Over the 
last few decades, Malaysia had experienced a rapid demographic and socio-economic 
change due to the inevitable migration from rural to urban areas (Ali et al., 1993). 
CVDs are the leading cause of death for 16.7 million people around the globe 
according to the WHO estimates. Deaths from CVD are twice now in developing 
countries. In addition, there is a concern regarding high CVD deaths among early age 
compared with those in the developed regions. By 2020, WHO predicts almost 25 
million CVD deaths worldwide (Mackay et al., 2004). CHD has no gender, 
geographic, or socioeconomic boundaries (World Health Organization, 2011). 
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In Malaysia, chronic diseases accounted for 71% of all deaths and by 2002, 30% of 
them died because of CVD (National Heart Association of Malaysia, 2008). It is 
estimated that by 2020, CHD and other non communicable diseases are predicted to 
account for seven out of every ten deaths in the Asia-Pacific countries. Malaysia is 
experiencing a rise in heart diseases despite improvement in health services and 
facilities. Heart diseases are considered as the second leading cause of death in 2006, 
accounting for 15.5% of those who died in government hospitals (National Heart 
Association of Malaysia, 2008). 
Epidemiologic studies have indicated that the mortality from CVDs is more than 
double in patients with diabetes compared to patients without diabetes. In addition, 
the premature death from cardiovascular complications is very common among 
patients with type 2 diabetes (Leiter, 2005). 
1.5 Pathophysiology  
Type 2 diabetes mellitus is a heterogeneous group of metabolic disorders. The 
metabolic disorders are a result of the combination of resistance to insulin action and 
inadequate insulin secretion with varying prevalence among different ethnic groups. 
These disorders are characterized by hyperglycaemia and associated with 
microvascular (i.e., retinal, renal, possibly neuropathic), macrovascular (i.e., 
coronary, peripheral vascular), and neuropathic complications (Mahler and Adler, 
1999).  
Patients with type 2 diabetes differ from patients with type 1 diabetes mellitus, as 
they are not absolutely dependent upon insulin for life. However, many patients with 
type 2 diabetes are eventually treated with insulin, because they maintain the ability 
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to secrete some endogenous insulin, so they are require, but do not depend, on insulin 
(Mahler and Adler, 1999).  
The pathophysiology of type 2 diabetes mellitus is characterized by impaired 
regulation of hepatic glucose production, and declining ß-cell function, 
ultimately 
Atherosclerosis is the main cause of CHD. The process of developing atherosclerosis 
begins from the endothelial function disruption. This occurs through lipoprotein 
droplets accumulations in the coronary vessels intima. The replication of the cells 
leads to the formation of the fatty streak which considered as the earliest visualized 
lesion of atherosclerosis (Libby and Theroux, 2005). Then, the fatty streak is then 
transformed into the fibrous plaque. Fibrous plaque is made up mainly by collagen 
and proteoglycan secreted by the smooth muscle cells. At this point the lesion starts 
affecting the vessel lumen (Lilly, 2003; Libby and Theroux, 2005; McPhee et al., 
1997; Kanjilal et al., 2008). The characteristics of coronary lesions in patients with 
diabetes compared with non-diabetics have several important distinctions.  Lesions in 
patients with diabetes have more extensive and diffuse atherosclerosis, smaller 
vessels containing longer lesions, impaired vascular remodeling with greater luminal 
leading to ß-cell failure. Furthermore, primary events are characterized by 
combination of peripheral insulin resistance and inadequate insulin secretion by 
pancreatic beta cells. In addition to the elevated levels of free fatty acids in plasma, 
insulin resistance also decreases glucose transport into muscle cells. Moreover, 
elevated hepatic glucose production and increased lipolysis is mainly attributed to 
insulin resistance. Type 2 diabetes develops when insulin secretion cannot increase 
sufficiently to compensate the insulin resistance. The insulin concentrations may be 
high, yet inappropriately low for the glycaemia level (Mahler and Adler, 1999; 
McPhee et al., 1997; Epstein et al., 1992; Lilly, 2003). 
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encroachment, impaired collateral vessel formation and higher coronary calcification 
scores (Lilly, 2003). 
The coronary plaque in patients with diabetes seems more liable to rupture owing to 
a thin fibrous cap, more inflammatory cells and smooth muscle cells. It has been 
reported that patients with diabetes without MI had higher levels of fibrinogen and 
plasminogen activator inhibitor-1 (PAI-1), markers of hypofibrinolysis and 
hypercoagulability that are also associated with atherosclerosis and MI, when 
compared with non-diabetic patients with MI (Lilly, 2003).  
The major CHD risk factors in patients with type 2 diabetes are hyperglycaemia, 
insulin resistance syndrome, hypertension, dyslipidaemia, smoking, obesity and lack 
of exercise, gender, age, family medical history of heart disease and enlarged heart 
(Turner et al., 1998b; Krentz et al., 2005) . 
1.6      Coronary heart disease risk factors 
1.6.1 Hyperglycaemia  
The measurement of glycaemia in the form of glycated haemoglobin (HbA1c) is now 
accepted as a benchmark of glycaemic control of patients with diabetes (The 
Diabetes Control Complications Trial Research Group, 1993). There is also an 
indication that HbA1c provides important information to providers and patients 
considering both health status and medical care charges in future (Gilmer et al., 
1997). Glycated haemoglobin is made up of the slow, non-enzymatic reaction 
between haemoglobin and glucose (Bunn, 1981). The rate of synthesis of glycated 
haemoglobin is mainly related to the plasma glucose concentration. Glycated 
haemoglobin measurement is broadly used for routine monitoring of long-term 
glycaemic status in patients with diabetes. Glycated haemoglobin is a clinically 
 9 
useful indicator of mean glycaemia during the preceding 120 days, which is the 
average erythrocytes life span (Goldstein et al.; 2004, Bunn, 1981; Jovanovic and 
Peterson, 1981; Nathan et al., 1984; Cefalu et al., 1994). 
Hyperglycaemia is the biochemical hallmark of diabetes. However the links between 
hyperglycaemia and excess CVD remain incompletely delineated (De Fronzo, 2004). 
In spite of that, chronic hyperglycaemia as evaluated by the level of HbA1c has been 
shown to relate tightly to the microvascular complications development of diabetes 
(Klein et al., 1996). Researchers showed that patients with diabetes with the highest 
blood glucose level have the highest complications incidence (Stratton et al., 2000). 
A meta-analysis reported that there is 18% (95% CI 10%-26%) increase in risk for 
CVD outcomes for every 1% increase in HbA1c (Selvin et al., 2004).  
Several potential pathogenic suggest a casual association between hyperglycaemia 
and vascular disease. Hyperglycaemia leads to accelerated formation of advanced 
glycation end products (AGE), formation by AGE of irreversible abnormal deposits 
in the subintimal layers of blood vessels, interference by these deposits with cellular 
interactions and generation of toxic reactive oxygen species modification of LDL-
cholesterol particles through glycation, making them more susceptible to oxidation, 
thickening and leakage of the vasculature due to cross-linking of vascular proteins by 
AGE, activation of protein kinase-C leading to increased vascular permeability and 
hyperglycaemia could cause activation of the pylol pathway with secondary cellular 
osmotic and ionic changes (Voulgari et al., 2010; Hoffbrand et al., 2005). 
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1.6.2 Hypertension 
Hypertension considered as a silent disease and simply an absence of routine check-
up lead to many undiagnosed hypertensive cases (Akter et al., 2010). In addition, 
hypertension may also interrelate with other CHD risk factors to speed up CHD 
development (Ministry of Health Malaysia, 2008a). The prevalence of hypertension 
in Malaysia is between 14.0 - 24.1% (National Health and Morbidity Survey III, 
2006). Around 65% of patients with type 2 diabetes of more than 30 years duration 
have hypertension (El-Atat et al., 2003). It is thought that high blood pressure 
accounts for up to 75 % of added cardiovascular risk in people with diabetes, 
contributing significantly to the overall morbidity and mortality (Epstein, 1997). In 
addition, a combination of hypertension and diabetes causes a high risk of CVD 
(Morrish et al., 1990; Prevost et al., 2005).  
Sustained blood pressures of 120-139 mmHg systolic, or 80-90 mmHg diastolic are 
now regarded as “pre-hypertension” for patients with no diabetes.  For any given 
level of blood pressure, however the clinical impact is greater in the presence of 
diabetes and especially when accompanied by nephropathy (Chobanian et al., 2003). 
The pathophysiological mechanisms of hypertension-mediated tissue damage in 
patients with diabetes include impaired vascular auto regulation which allows 
transmission of high systemic blood pressure to the microvasculature, decreased 
vascular compliance (decreased compliance of major vessels, for example the aorta, 
perhaps resulting from non-enzymatic glycation of vessel wall proteins) which may 
tend to higher central pressures, endothelial dysfunction which is associated with 
impaired endothelial responses and sodium retention which reflects  
hyperinsulinaemia effects of renal ion handling. Hypertension in patients with type 2 
diabetes tends to be characterized by sodium retention and volume expansion. Severe 
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hyperglycaemia which is a risk of insulin therapy may be associated with acute 
changes in blood pressure (Stern et al., 2004; Sobel and Schneider, 2002). 
1.6.3 Dyslipidaemia 
The risk of any level of lipid profile variables is higher in the diabetic population 
than general population (Kon, 2005). Patients with type 2 diabetes tend to have the 
same lipid profile as individuals with atherogenic profile having abdominal obesity 
and insulin resistance (Carr and Brunzell, 2004). Patients with treated diabetes do not 
usually have raised absolute levels of total or LDL-cholesterol (Krentz, 2003). 
Patients with type 2 diabetes more often have raised levels of fasting and 
postprandial triglycerides; this is generally accompanied by a low plasma 
concentration of cardio protective healthy HDL-cholesterol. A high plasma 
triglyceride concentration is a risk factor for CHD (Austin et al., 1998).  
Triglyceride could be directly associated to the development of coronary atheroma. 
Therefore, low triglyceride could be the key feature underlying the development of 
CHD in patients with insulin resistant (Austin et al., 1998; Ginsberg, 2000). 
Low levels of HDL-cholesterol are closely associated with increased risk of CHD in 
both diabetic and non-diabetic populations. There are several reasons for these 
apparent protective properties of HDL-cholesterol. There are many reasons behind 
the protective features of HDL-cholesterol. The main function of HDL-cholesterol is 
to deliver cholesterol to the liver for excretion, it may also have anti-inflammatory 
and antioxidant properties, protecting against atheromatous disease (Barrett Connor 
et al., 1982). 
The pathophysiology of dyslipidaemia in diabetic population revolves around 
circulating insulin which is in healthy people responsible for adipocyte lipid 
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metabolism. The fatty acids liberated by impaired actions of insulin in adipocytes 
have been implicated in a diverse range of defects in type 2 diabetes, ranging from 
hypertriglyceridaemia to impaired insulin secretion and endothelial dysfunction. 
Insulin causes the suppression of intra-adipocyte hormone-sensitive lipase in the 
postprandial period, preventing lipolysis and result in the release of fatty acids. 
Higher insulin levels stimulate intravascular lipoprotein lipase which accompany the 
early postprandial period. This increases triglyceride clearance from chylomicrons 
and very low density lipoprotein (VLDL-cholesterol) particles into adipocytes and 
minorly into myocytes. Consecutively insulin stimulates intra-adipocyte 
esterification of fatty acids forming new intra-adipocyte triglyceride stores (Stern et 
al., 2004). 
The defects that are encountered in type 2 diabetes include increased hepatic 
synthesis and secretion of large VLDL-cholesterol particles, increased residence time 
of triglyceride rich particles, increase triglyceride –cholesterol ester exchange, 
relatively cholesterol-depleted HDL-cholesterol and LDL-cholesterol (Stern et al., 
2004; Sobel and Schneider, 2002). 
1.6.4 Gender 
Males and females share a lot of CHD risk factors such as age, dyslipidaemia, 
hypertension, smoking, diabetes, obesity and physical inactivity. But the use of 
contraceptives and the reduction of ovarian function with age considered as an 
additional risk factors for females (Bush et al., 1988).Women with diabetes had a 
CVD events risk similar to those without diabetes but with prior CHD. For men with 
diabetes, the CV events risk was half for men without diabetes who had known CHD 
(Becker et al., 2003).The alterations in triglycerides and HDL-cholesterol observed 
among patients with type 2 diabetes tend to be more marked in women than men. 
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This may be part of the explanation for the greater relative risk for women with 
diabetes (Juutilainen et al., 2004). Middle aged women with diabetes are more likely 
to have high blood pressure than men (Hypertension in Diabetes Study, 1993).    
1.6.5 Obesity 
Obesity is rapidly becoming one of the most important problems globally and in 
Malaysia as well. It is an important contributory factor to diabetes. The worldwide 
prevalence of overweight (body mass index (BMI) ≥25.0 kg/m2) and obesity (BMI ≥ 
30.0 kg/m2) is estimated at more than 1.1 billion. Newly, the risk of obesity related 
diseases among Asian have rises from a lower BMI of 23 kg/m 2 (James et al., 2002). 
In Malaysia, the prevalence of obesity (BMI>30 Kg/m2) in 1996 was 4.4% and 
overweight (BMI 25– 30 Kg/m2) was 16.6%. Moreover, urban areas showed higher 
prevalence rates of overweight individuals (17.4%) compared to their rural 
counterparts (15.5%) (Zaini, 2000). This indicates the high prevalence of overweight 
and obesity in Malaysia which is much more serious than what has been reported in 
countries around the region. Singapore and Malaysia had the highest levels of 
overweight and obesity within the region. Malay ethnic origin shows significantly 
higher body weights than those of Chinese or Indian background (Gill, 2006). T
When the energy intake from food and drink exceeds energy expenditure from 
physical activity and other metabolic processes, weight gain and obesity develop. 
The economic transition that has been developed in recent years causes a rapid 
change in lifestyle which represents the most likely cause for the increase in 
population weight in Asia. Diet and levels of physical activity have changed due to 
he 
National Health and Morbidity Survey in Malaysia 1996 reported that in adult 
females showed higher prevalence rates of overweight and obesity than male adults 
(Lim et al., 2000).  
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modernization throughout Asia. Traditional foods such as fresh fish, meat, and local 
fruits and vegetables of past generations have been replaced by rice, sugar, flour, 
canned meats, canned fruits and vegetables, soft drinks and beer (Gill, 2006). 
Definitely the consuming of larger amounts of fats, oils, meat, sugar and less 
vegetables and cereals happened more than in the past (Drewnowski and Popkin, 
1997). In addition, the leisure time activities have been changed from the past by 
which television; computers and videos are becoming the preferred activities 
throughout the region. Furthermore, motorized transport has replaced bicycles (Bell 
et al., 2002).  
The increase in BMI causes an increase in the risk of hypertension (Ascherio et al., 
1996). The association between hypertension and obesity is characterized by an 
increase in vascular volume. Many pathological mechanisms could be associated in 
the development of hypertension in individuals with obesity which is increased renal 
sodium and water absorption, sympathetic nervous system activation, changes in 
Na+/H+-ATPase activity, and growth factor–mediated structural changes to the 
vascular wall. Hyperinsulinemia considered a contributing factor in each case 
(Redon, 2001). 
Increased free fatty acids observed in individuals with obesity contribute to the 
defects in glucose use and storage. The increase in body fat causes an increase in the 
rate of lipolysis. This leads to increased free fatty acid mobilization and consequently 
to increased free fatty acid oxidation in muscle and liver. As a consequence, glucose 
use by muscle decreases because of the use of free fatty acid as an alternate energy 
source, and hepatic glucose production increases in response to the higher free fatty 
acid oxidation. These actions result in hyperglycaemia and impaired glucose 
tolerance (Jensen et al., 1989). 
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It also affects lipid metabolism by increasing very-low-density lipoprotein 
production by the liver, reducing HDL-cholesterol levels, and increasing the number 
LDL-cholesterol particles. These changes in lipoprotein profile and glycaemia are 
associated with increased risk of CHD (Despres, 1994).  
1.6.6 Age 
Age is the one of the strongest predictors of CHD risk. Most men by age 65 have a 
20% risk of a CHD event during the next 10 years (Booth et al., 2006). Clinical 
guidelines recommend that type 2 diabetes individuals be regarded as a high-risk for 
CHD if they are older than 40 years of age (American Diabetes Association, 2009).  
1.7 Prevention 
It has been clarified that vascular complications risk increases constantly with rising 
of risk factors in patients with type 2 diabetes, in spite of the absence of the natural 
thresholds by which vascular complications risk are prevented completely. The 
microvascular and macrovascular complications are developed by the synergistic 
contribution of poor glycaemic control, hypertension and hyperlipidaemia in patients 
with type 2 diabetes (Adler et al., 2000; Stratton et al., 2000).  
Harmonization between effective risk factor management plans for patients with 
diabetes is very important. The management includes steps to maintain glycaemic 
control, lower blood pressure, reduce LDL-cholesterol levels, smoking cessation and 
increase physical activity (O'Connor et al., 1998; American Diabetes Association, 
2003). Vascular protective measures such as statins, angiotensin-converting enzyme 
(ACE) inhibitors and lower blood pressure targets, are advised for all patients with 
high risk of CHD. For intermediate CHD risk, pharmacological measures depend 
upon the severity of the associated risk factors. Moreover, low risk population has 
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less advantages from pharmacological vascular protection, as the treatment hazards 
may exceed the advantages and unlikely to be cost effective (National Cholesterol 
Education Program Expert Panel on Detection Evaluation and Treatment of High 
Blood Cholesterol in Adults, 2001; McPherson et al., 2006). 
In spite of the arguments regarding the 10 year predicted risk level (>15%, or >30%) 
at which primary prevention of CHD, using aspirin and/or statins, should be started 
(Collins et al., 2003; Jackson, 2000). The National Institute for Health and Clinical 
Excellence (NICE) guidance and supported by the National Service Framework 
(NSF) for diabetes have lowered the calculated 10-year CHD risk level threshold for 
pharmacological intervention to 15% in patients with diabetes as opposed to the 30% 
10-year CHD risk level applied in the general population (Guzder et al., 2005; 
National Institute for Clinical Excellence, 2002).  
1.7.1 Role of diet and exercise  
A combination of weight loss and increased exercise levels are the most effective 
strategies to help patients reaching their targets of lowest risk of progression. 
Physical activity may lead to improvements in blood pressure, lipids profile, insulin 
sensitivity and body weight. In addition, it may improve endothelial function, 
coronary blood flow, reduce levels of inflammatory markers and thrombotic risk. 
Regular exercise also plays an important role in cardiac rehabilitation after Ml and in 
the treatment of intermittent claudication. Obesity is a most important cause of 
acquired insulin resistance. In addition, obesity aggravates many risk factors for 
CHD. In spite of the advantages of weight loss on glycaemia, lipids, blood pressure, 
inflammatory markers and other risk factors, treatment generally stays far from 
satisfactory. Low-carbohydrate diets and anti-obesity drugs (like orlistat) are 
important solutions to be considered with obesity (Krentz et al., 2005). 
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1.7.2 Hyperglycaemia management 
Hyperglycaemia influences the biochemical parameters and affects the progression 
of CHD and mortality rates in individuals with diabetes (Van der Does et al., 1998; 
Herman, 1999). The results from the United Kingdom Prospective Diabetes Study 
(UKPDS) indicated that by lowering the concentration of blood glucose, the risk of 
diabetic complications reduces (Stratton et al., 2000). Controlling hyperglycaemia by 
aggressive treatment is much more effective in lowering the number of complications 
than standard treatment (Van der Does et al., 1998; Herman, 1999).  
There are important oral anti-diabetic agents that are used for controlling the 
glycaemia such as sulphonylureas (first generation e.g. tolbutamide, chlorpropamide 
and second generation e.g. glibenclamide glipizide gliclazide glimepiride), rapid 
acting insulin secretagogues (e.g. repaglinide, nateglinide), biguanides (e.g. 
metformin), alpha-glucosidase inhibitors (acarbose, miglitol, thiazolidinediones e.g. 
rosiglitazone, pioglitazone) (Ministry of Health Malaysia, 2009b). 
1.7.3 Hypertension management 
Recent clinical trials have informed target blood pressures and have helped to 
identify the drugs that are most advantageous in diabetes population (Galzerano et 
al., 2010). For achieving blood pressure targets in many patients, it is recommended 
to use two or more drugs from different classes.  The important issue that should be 
considered is the level of blood pressure attained, rather than the drugs selection with 
particular modes of action (Brown et al., 2003). The 2004 American Diabetes 
Association (ADA) guideline (Adams et al., 2008; Arauz-Pacheco et al., 2004), 2004 
British Hypertension Society (BHS) (Ramsay et al., 1999; Williams et al., 2004) and 
the Joint National Committee Report (Chobanian et al., 2003) recommend a target of 
<130/80 mmHg for patients with diabetes. The ADA recommends using an 
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angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers 
as first-line therapy. While in practice, the first choice for many physicians would be 
a low-dose of diuretic.  
Non-pharmacological measures are regarded as the cornerstone of therapy, although 
its benefits are often underestimated and rarely attained. Reduction in body weight 
for obese and overweight patients by having a regular aerobic physical exercise 
could be beneficial. Reduced dietary salt intake and increased potassium intake 
through eating fresh fruit and vegetables would be very helpful. If drug therapy is 
necessary for most patients; non-pharmacological measures would be very useful for 
limiting the need for medication (Sobel and Schneider, 2002).  
1.7.4 Dyslipidaemia management 
Lipid lowering should have a significant place in the primary prevention of CVD in 
patients with diabetes. Most of the evidence favoring lipid-lowering relates to the use 
of statins (Vijan and Hayward, 2004). Trials that involved participants with diabetes 
and CHD have shown that cholesterol lowering with statins substantially lowers the 
risk of subsequent cardiovascular events (Welch, 2004).  
However, in spite of increasing evidence and knowledge of the lipid lowering value, 
a recent survey of diabetes specialists showed that many patients with diabetes still 
remain untreated or undertreated. Moreover, the current lipid lowering prescription 
rates in patients with diabetes remain low, even in patients with CVD (Leiter, 2005). 
An estimated 70–97% of patients with type 2 diabetes have a dyslipidaemic profile 
(Fagot-Campagna et al., 2001). It has been clarified that statins therapy is very 
beneficial in both primary and secondary prevention of cardiovascular events 
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especially in those with diabetes (Sacks et al., 2000; Collins et al., 2003; Lindholm, 
2003; Goldberg et al., 1998).  
Non-pharmacological measures involves dietary measures which is attaining ideal 
body weight, reducing saturated fat consumption to around 30% of total calories, 
increasing intake of monounsaturated, avoiding trans-fatty acids. Excessive alcohol 
consumption may exacerbate hypertriglyceridaemia (Krentz et al., 2005). The 
UKPDS showed that three months' diet therapy in newly diagnosed patients with 
diabetes resulted in a reduction in mean plasma triglycerides with minor 
improvements in total cholesterol. Body weight was reduced by a mean of 5% and 
fasting plasma glucose was reduced (Manley et al., 2000).  
1.8 Prediction engines 
The prediction of CHD goes back to the development of epidemiological and 
biostatistical methods. These methods permitted the evaluation of the factors that can 
identify the risks of a specific outcome over time. They also involve a suitable study 
design that recruits individuals who are free of the particular vascular event of 
interest, acquiring baseline data on factors that might influence risk for the 
outcome, and following the participants prospectively for the clinical outcome 
development under investigation (Wilson et al., 1998). By 1991, Framingham CHD 
risk score were published to assess the risk of CHD by predicting the total CHD 
(Anderson et al., 1991b) and a variety of first cardiovascular occurrences (Anderson 
et al., 1991a). Specialized models were developed for subjects with type 2 diabetes 
that consider additional potential predictor variables. The authors have suggested that 
the main predictor variables for initial CHD events were sex, age, ethnicity, smoking 
status, HbA1c, time since the diagnosis of diabetes, systolic blood pressure, and the 
levels for lipids (Stevens et al., 2001). 
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Currently, there are many risks tables and equations have been proposed for the 
purpose of CHD prediction; the most famous and most commonly used is 
that derived from the Framingham (Kannel et al., 1976), SCORE (Systematic 
Coronary Risk Evaluation) (Conroy et al., 2003), and United Kingdom Prospective 
Diabetes Study (UKPDS) studies (Stevens et al., 2001; Kothari et al., 2002), and the 
last has been developed specifically for diabetic sub-populations.  
Clinicians are capable of using CHD risk score models to help them to estimate the 
absolute risk of CHD in a given patient. Risk estimation allows a more defined 
estimate than ‘high risk’ as well as risk communication to patients may itself 
encourage health (Roach and Marrero, 2005). Patients with type 2 diabetes have a 
higher risk of CHD than general population which makes the intervention 
increasingly important in diabetic population (Koskinen et al., 1992; MRC Working 
Party, 1992; Turner et al.; 1998a).  
The U.K. Prospective Diabetes Study (UKPDS) is randomized landmark controlled 
trial. It indicated that both intensive treatments of blood glucose and of blood 
pressure in diabetes can decrease the risk of diabetes-related complications in newly 
diagnosed patients with type 2 diabetes (Unnikrishnan, 1998; UKPDS Group, 
1998). In addition to giving answers to questions related to therapy issue, 5102 
cohort UKPDS patients were followed for a median of 10.7 years, providing 
excellent opportunity for a natural history description of treated disease (Adler et al., 
2000; Stratton et al., 2000). In quantitative terms, UKPDS investigators described the 
connection between risk factors and the over time presence of diabetic 
complications. The UKPDS risk engine corporate mathematical equations into a 
model which calculates the absolute risk of incident CVD (Adler, 2008b). 
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1.9  Rational of the study 
Diabetes is known to increase the risk for CHD 2- to 3-fold and when patients with 
diabetes develop overt CHD, the prognosis will be much worse than it is for patients 
without diabetes (Barrett-Connor et al., 1991; Koskinen et al., 1992; Manson et al., 
1991). The most effective management of diabetes revolves around prevention, so 
CHD risk estimation is recommended as a strategy to identify high-risk patients who 
would be the major beneficiaries of priority interventions (Kannel et al., 1976; Fuller 
et al., 1983). Although advances in recent years in CHD prevention and the 
associated decrease in mortality from the disease, patients with type 2 diabetes have 
had a lower reduction and an increase in mortality rate (Gu et al., 1999). To date, the 
assessment of CHD risk in patients with type 2 diabetes has been very limited 
worldwide (Winocour and Fisher, 2003). Furthermore, there is no published data in 
Malaysia that evaluates CHD risk among type 2 diabetes and addresses CHD risk in 
type 2 diabetes as a problem. Based on that, the present study evaluates the absolute 
levels of 10-year CHD risk among patients with type 2 diabetes in Hospital Pulau 
Pinang using the diabetes specific UKPDS risk engine. In addition, this study 
investigates target outcome for the cardiovascular risk factors according to the 
Malaysian Diabetes Guideline among type 2 diabetes population of the study. 
The results of this study could be used as a baseline for future studies that focused on 
cardiovascular complications in patients with type 2 diabetes. It could also support 
the background of the practitioners about the risk factors and the importance of 
assessing CVD in patients with type 2 diabetes. It could help to prevent 
cardiovascular development since the most effective management of diabetes 
revolves around prevention.  
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1.10  The study objectives 
The objectives of this study are to: 
1-Estimate the predicted 10-year CHD risk among patients with type 2 diabetes using 
the diabetes specific UKPDS risk engine calculator.  
2-Examine the target outcome for the CHD risk factors in patients with type 2 
diabetes according to the Malaysian Diabetes Guideline. 
3-Evaluate the factors associated with the predicted 10-year CHD risk score among 
patients with type 2 diabetes. 
4-Investigate the association of glycaemic control with CHD risk. 
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 CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Introduction  
Patients with type 2 diabetes have high prevalence of CHD than the general 
population (Barrett-Connor et al., 1991; Koskinen et al., 1992; Manson et al., 1991)
2.2 Literature review  
. 
Interventions are strongly important and proved to be beneficial in general 
populations and mostly in diabetic populations (Pyorala et al., 1997; MRC Working 
Party, 1992; Shepherd et al., 1995; Turner et al., 1998a; Mann, 2000). Patients with 
type 2 diabetes should have their CHD risk assessment checked routinely for 
determining the optimal care (Brown et al., 2000). 
The U.K. Prospective Diabetes Study (UKPDS) is a prospective observational study 
cohort of 5102 patients in 23 hospital based clinics in England, Scotland and 
Northern Ireland, followed for a median of 10.7 years (Adler et al., 2000; Stratton et 
al., 2000). It aimed to test whether type 2 diabetes complications occurrence is 
reduced by allocated treatment for diabetes (Unnikrishnan, 1998; UKPDS Group, 
1998). As a conclusion the trial showed that both intensive treatments of blood 
glucose and of blood pressure in diabetes can reduce the risk of diabetes-related 
complications in newly diagnosed subjects with type 2 diabetes. It also participated 
essentially to understand the prognosis of diabetic complications by recording the 
clinical characteristics, and then outcomes (Unnikrishnan, 1998; UKPDS Group, 
1998).  
UKPDS reported that the risk of CHD increases approximately 11% for each 1% (1 
unit) increase in glycated haemoglobin (HbA1c) which reflects the glycaemia 
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contribution itself. In addition to hyperglycaemia, high levels of LDL-cholesterol, 
low levels of HDL-cholesterol, hypertension and smoking status had been proposed 
by UKPDS as modifiable predictors. 
 The association between risk factors and the occurrence of diabetic complications 
over time was described in quantitative terms (Turner et al., 1998b; Barrett-Connor 
and Wingard, 1983). The UKPDS risk engine combined mathematical equations into 
a model that estimates CHD and stroke risk (Stevens et al., 2000; Stevens et al., 
2004; Stevens et al., 2001; Kothari et al., 2002).  
There are other models that existed before UKPDS risk engine but are different by 
which they may not have considered a measure of glycaemia (Anderson et al., 
1991a), or the estimates derived from the model was from small, localized 
populations, which probably were not appropriate for the populations to which it was 
applied (Eastman et al., 1997).   
Moreover, Coleman et al. suggested in his report that Framingham, SCORE, and 
DECODE (Diabetes Epidemiology Collaborative Analysis of Diagnostic Criteria in 
Europe) risk equations are not reliable for the estimation of cardiovascular risk in 
patients with type 2 diabetes (Coleman et al., 2007). The widely-used Framingham 
models are not specifically designed for subjects with type 2 diabetes and derived 
from a population with only 337 patients with type 2 diabetes (Anderson et al., 
1991a; Anderson et al., 1991b). It employs dichotomous variables for glycaemia, 
presence or absence of diabetes which implies that CHD risk increases in patients 
with diabetes similarly despite of glycaemic control or diabetes duration (Myers et 
al., 2000), while UKPDS includes glycaemia as a continuous variable and time since 
diagnosis of diabetes (Feher and Elkeles, 1999).  
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In addition, there is the Prospective Cardiovascular Munster (PROCAM) model 
which is derived only from men data in that study and this score includes 
triglycerides, LDL-cholesterol and HDL-cholesterol, but not total cholesterol or 
glucose concentrations (Assmann et al., 1999).  The 10-year European SCORE 
project included the classic risk factors which are sex, age, systolic blood pressure, 
smoking status and either total cholesterol or total HDL-cholesterol but diabetes was 
not included because of lack of comparable data in the individual studies (Balkau et 
al., 2004). DECODE equation recruited over two thousand patients with diabetes in 
the study, but fasting plasma glucose was incorporated in a categorical manner which 
therefore does not adequately consider the effect of glycaemia different levels 
(Balkau et al., 2004; Coleman et al., 2007). 
Mafauzy et al. conducted a study in Kelantan enrolling 2508 participants. The study 
aimed to determine the prevalence of type 2 diabetes and impaired glucose tolerance 
and their association with cardiovascular risk factors. The patients were asked to 
come to the local health clinic for interviewing and physical examining. Blood was 
collected for glucose, triglyceride, total cholesterol, LDL-cholesterol, HDL-
cholesterol, urea, creatinine and uric acid determination. The results of the study 
showed that patients with type 2 diabetes had significantly higher mean BMI, 
systolic blood pressure, diastolic blood pressure, serum urea, triglyceride, cholesterol 
and LDL-cholesterol and lower mean serum HDL-cholesterol than the normal 
subjects. Females showed significantly a higher obesity than males. As a conclusion, 
the study indicated that patients with type 2 diabetes showed a high prevalence of 
obesity, hypertension and hypercholestrolaemia (Mafauzy et al., 1999). 
In Trinidad, a study was conducted to evaluate the long-term glycaemic control and 
risk of CVD in multi-ethnic groups for patients with type 2 diabetes (Ezenwaka and 
